DR10624, a First-in-Class FGF21/GLUCAGON/GLP-1 Receptor Triple Agonist, Significantly REDUCED Triglycerides, Lipids, and Liver Fat in Patients with Severe HYPERTRIGLYCERIDEMIA
Key Points: DR10624 is a first-in-class triple agonist of the FGF21, glucagon,…
Novel siRNA targeting therapy lepodisiran results in a dose-dependent and sustained reduction in Lipoprotein(a)
Key Points: There are currently no approved targeted therapies for the reduction…
EPIC-STEMI: Early Routine PCSK-9 Use Added to High Intensity Statin Reduces LDL after Primary PCI for STEMI
Key Points: Early high-intensity statin therapy is standard of practice in acute…
Relationship Between Omega-3 Fatty Acid Levels And Major Adverse Cardiovascular Outcomes In Patients With High Cardiovascular Risk
KEY POINT: There is not enough evidence to state whether Omega-3 Fatty…
TIPS-3 Trial: The Combination of Polypill and Aspirin Administered to Patients at Intermediate Risk Led to a Lower Incidence of Cardiovascular Events Compared With Double Placebo
A recent trial by Dr. Salim Yusuf, published in The New England Journal…
PREMIER Trial Shows Incremental Plaque Regression by a Single Lipid Apheresis and Maintained Statin Therapy in ACS Patients Treated With PCI
A recent study by Dr. Banerjee, published in Circulation: Cardiovascular Interventions, demonstrated…
ORION-1: 1-Year Follow-Up Data Affirms 2-dose Regimen Using 300 mg of Inclisiran For Persistent LDL-C Lowering
A randomized, double blind, placebo-controlled, phase II clinical trial studying the effect…
EWTOPIA 75 Trial: Lowering LDL-Cholesterol with Ezetimibe Prevents Cardiovascular Events in the Elderly
Individuals older than 75 years treated with ezetimibe had a significantly lower…
Positive Correlation Found Between Combined Life-time Exposure of Decreased LDL-C and Low Systolic BP in Lowering the Risk of Cardiovascular Disease
A recent study by Brian A. Ference et al. based on a…
HOPE 4: A Comprehensive Community-based Program Surpassing the Barriers in Improving BP Control and Associated Cardiovascular Disease Risk in 2 Middle Income Countries
Significant improvement in blood pressure control and related cardiovascular disease (CVD) risk…
IMPROVE-IT Trial: Intensive Lipid-Lowering Cuts CVD Risk in the Elderly
Among patients hospitalized for an acute coronary syndrome (ACS), adding ezetimibe to…
Cohort Study Shows That a New HDL Apolipoproteomic Score Correlates with Both Risk of Coronary Artery Disease and Risk of Cardiovascular Death
In a study led by Dr. Pradeep Natarajan showed that an HDL…
Nationwide Study Shows Pharmacy Closure Associated with Significant Decrease in Adherence to Cardiovascular Medications
According to a new national study led by Dr. Dima M. Qato…
Study in China Indicates Current Practice of Lipid-Lowering Treatment Needs Improvement
In an article published in the American Heart Journal, Dr. Yueyan Xing…
Total Event Analysis from REDUCE-IT Showcases a Substantial Reduction in the Burden of Ischemic Events, Experts Debate Possible Mechanisms of Action of Icosapent Ethyl
The total event analysis from the REDUCE-IT trial, presented at ACC 2019…
Statin vs Healthy Adherer Effect On Mortality in ASCVD
In a vigorous retrospective cohort study published in JAMA, Fatima Rodriguez et…
Statins Shown to Reduce Major Adverse Cardiovascular Events in Patients Older Than Seventy Five Years
HMG-CoA reductase inhibitors or as they are commonly known as statins have…
Coronary Artery Calcium Scoring: A Screening Tool For Statin Prescription In the Primary Prevention of Cardiovascular Disease?
According to a new study published in the Journal of American College…
The Latest Incarnation of the Blood Cholesterol Management Guideline 2018: Numbers Matter, Lower LDL-C is better
The AHA/ACC 2018 guideline on the management of blood cholesterol, endorsed by…
CoQ10 supplementation: A Remedy for Statin‐Induced Myopathy?
A meta‐analysis performed by Choi et al., the results of which were…